Home
This site is intended for healthcare professionals

Primary Care Obesity Roadmap Australia: Module 1 Early Recognition and Prioritization

Share

Description

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join primary care practitioner Dr. Ralph Audehm for this educational module designed to equip healthcare providers with actionable, evidence-based strategies for recognizing and prioritizing clinical obesity as a complex chronic disease. Centered around a realistic patient case study, this session guides clinicians through identifying obesity-related complications beyond standard BMI metrics, mitigating implicit healthcare biases, and implementing structured shared decision-making frameworks to collaboratively establish patient-centered, long-term treatment goals.

Session Highlights

  • Redefining Clinical Obesity Assessment: Move beyond the limitations of standard BMI criteria by integrating comprehensive measures of excess adiposity, such as waist circumference, and systematically identifying mechanical, cardiometabolic, and functional complications to accurately diagnose clinical obesity.
  • Overcoming Weight Bias and Stigma: Learn to recognize and mitigate implicit biases within the healthcare setting by employing person-centered, non-judgmental language, acknowledging a patient's prior negative clinical experiences, and actively asking for permission before initiating weight-focused discussions during routine or acute visits.
  • Implementing Structured Shared Decision-Making (SDM): Master collaborative clinical frameworks to formulate highly individualized care plans that align directly with the patient's personal priorities, clearly present evidence-based therapeutic options, and establish realistic, health-focused targets rather than solely focusing on the scale.
  • Strategic Care Planning and Follow-Up: Discover how to seamlessly transition brief, acute care consultations—such as those for new-onset joint pain or medication refills—into dedicated, proactive follow-up visits specifically structured to manage obesity, monitor ongoing physical function, and adjust clinical interventions in a supportive, blame-free environment.

This is Module One of Four. Modules Two, Three and Four can be found here.

Prefer to read? see our Key Clinical Summary Here

Who Should Watch

This activity is intended for primary care providers, nurse practitioners, physician assistants/associates, pharmacists, and other healthcare providers who care for patients with obesity.

Faculty

Dr Ralph Audehm is a general practitioner who graduated from Melbourne University in 1984 and has worked for over 25 years in general practice. He is experienced in managing all types of patients. He obtained a Diploma from the Royal Australian College of Obstetricians and Gynaecologists in 1987 and is an Honorary Clinical Associate Professor at the Department of General Practice, University of Melbourne. He has had a long-standing interest in the management of chronic conditions in General Practice especially diabetes and heart disease.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Ralph Audehm, faculty for this educational activity, has the following relevant financial relationships: Advisory Board and Consultant for AstraZeneca, Boehringer Ingelheim, Lilly and NovoNordisk.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-292-H01-P

Type of Activity: Knowledge

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting September 10th 2026, and will expire on August 4th 2027.

Learning objectives

  1. Employ bias-aware communication and structured shared decision making (SDM) at the point of diagnosis, utilizing the patient's specific metabolic and mechanical complications to collaboratively set function-based goals for people with obesity, demonstrating correct application in > 75% of post-activity case assessments.

  2. Initiate guideline-concordant treatment plans – integrating pharmacotherapy, structured lifestyle interventions, and surgical referrals – while implementing workflows to monitor physical function and preserve body composition, achieving appropriate treatment decisions in > 75% of simulation scenarios.

  3. Apply structured reassessment algorithms to determine treatment efficacy, true therapeutic non-response amid weight plateaus, and timely treatment escalations in > 70% of longitudinal case exercises.

  4. Formulate proactive long-term adherence pathways — including proactive side-effect mitigation, the timely review of concomitant medications, and a patient-centered review of therapeutic options in > 75% of applied decision activities.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

Early recognition and prioritization, so the first poll, In a 10 minute clinic visit, in what circumstance do you raise the topic of obesity care, so they're your choices, so if the patient raises it, if the BMA is documented and relevant, if a complication maybe obesity related, if I can arrange a dedicated follow-up visit, or I usually avoid the topic. OK, so we're gonna do this like via a case there, so we've got a 51 year old uh lady who attends a routine primary care visit, new onset knee pain, and of course she's had hypertensions after repeat medication. She hasn't had a BMI or waist circumference recently documented, um, her BP is above target. And of course the knee pain is limiting um her walking and going up and down stairs. She does snore and has some daytime fatigue reported. And she's had a prior negative experience discussing weight with a healthcare professional, which unfortunately is something that a lot of our patients experience, um, also from a lot of our specialist colleagues, so it's something that we need to be aware of. So how do we assess, you know, uh clinic obesity, um, so we know it's a chronic disease, but we know BMI has its limitations, and we've known that for a while and we've sort of worked around it, um. But there are some new guidelines for us that I think are, are, are really good, and so they've come up with a definition ah of clinical obesity, which is a chronic illness, resulting from alterations in the function of organs or the whole organism. Directly induced by excess adipocity, independent of other adipocity related diseases, so, what they're talking about is an obesity phenotype, you know, with signs and symptoms or limitations of daily activities or a combination. And we'll go to um and these days I mean we've we've known about waist circumference for a long time, but so to fulfill this new criteria you still can use BMI but you must have some other measure of excess adipocity. So whether that be waist circumference, whether it be waist to hip ratio or waist to height ratio, or indeed if you're using something like DEXA. So this is how it sort of looks, so you screen, so you might start with a BMI within your practice, and then, you will then look at and say well, do they actually have um abnormal fat mass, and of course we're gonna do that like we said using, you know, the waist circumference or something related, so if they then have an excess of fat mass, then the next step is to say well, Is there any dysfunctional limitations associated with that? So, if someone has excess adiposity but has no impairment, well, They're labeling that as pre-clinical obesity because they haven't actually developed any issues, and so then you would do, you know, your normal sort of preventive sort of work, but if they already have some obesity related organ dysfunction and you can see there's a list there of what they would consider, um, obesity related complications and relevant to our lady is, The top two, the osteoarthritis, possibly of her knee, and of course she was snoring feeling fatigued, so possibly um obstructive sleep apnea, and then of course the diseases that we know are related to obesity on the right and of course if they've got those sort of complications we need to both treat the obesity as well as the underlying or the um associated condition. They've mentioned, you know, I, you've heard me mention obesity bias or prejudice, um this is something, um, that's very real, um, and a lot of our patients experience it, and sometimes they'll experience it, you know, even not overtly but by some of the things like, you know, I've had patients who sometimes I haven't had the right cuff size, because their arm's too big and it makes them feel, You know, bad in many ways, so we need to be aware of that weight stigma and we need to make sure that we're not adding to that and that we're coming to people in a very open, non-blaming mind, um, Because if we don't, if we perpetuate it, these people will avoid seeking help from healthcare professionals, they will get fewer screening exams, you know, for things like your CSTs and mammograms and blood pressures and so on. um, so it is really important that we are aware of this and, and make an effort to make sure that we're not even inadvertently um adding to that sort of stigma. So we all need to be aware of it, um, language does matter, um, and so, you know, the old adage like I can remember when I was young, you know, your weight is going to kill you or things like that, well, those sort of things don't work, so we need to be very mindful. Of how we talk to our patients about it and you know in many ways asking permission. So you know, do you mind if we talk about your weight today or you know I noticed that your BP is still high despite the medications, it's, do you mind if we discuss your weight cos I think that maybe having a role, you know, it's, you know, ah looking for that sort of permission and involvement, getting them along into that journey. And of course um that's interesting um they, you know, I tend not to use the term obesity cos I think many of them, many people actually look on that as being quite derogatory. Um, but certainly when we're talking to our colleagues, you know, talking to a person who has obesity but not some, you know, just trying to distinguish that it's not just that person, there, there is a person really attached to things and, you know, we've gone through this with diabetes and it's made a huge difference for a lot of our patients. So, um You know, shared decision making, and, and I think this is critical, this is something, you know, over, you know, 40 years of general practice that, you know, I finally, uh got it through my head that this was a really important um component of the way we deal with our patients and, you know, it's certainly got a great evidence base to it, it brings them along on the journey, it makes them involved and of course when they choose something that's, you know, That's their choice, they're far more likely to participate and do what, you know, we've actually come up together and it's not me telling them, it's actually often the patient opting for the range of options that I've given them. And of course one of the things that we are really lucky today is that we're having more and more choice when it comes to managing people um who are obese. So, um, and so basically what we do is, you know, we, we, we do our physical assessment, um, but we very much develop an individualized treatment plan and, and I know a lot of you primary care physicians out there are very good at this, um, we know this is how we engage with our patients and take them along the journey. And then of course the critical thing is following up, uh making sure that people are with us on the journey in the long time, that we do manage their weight loss and you know, we we're with them, we're not actually judging them, but we're with them, supporting them on a journey cos for many of these people, they have tried many times and they're always setting themselves up for failure because that's what's happened in the past, and we do need to counter that in a very mindful way. So, we have had some Australian guidelines, um, so you know, talking to people about the benefits of weight loss, um, so we know for ages, thanks to European and the Americans, we know the diabetes prevention programs, ah, work with as little as much as 5% weight loss, so, um, you know, talking about it in real terms, how it impacts upon them. And then, you know, making sure that there's nothing else, I mean, it's very rare to have medical conditions, but we've gotta be aware of certain groups of people and I think of people with low prevalence um mental health issues, um especially when they're on their, you know, antipsychotic and we know weight gain can be an issue and often talking to people early, before it becomes unmanageable is a really good thing, but then being with them and supporting them through that. Making sure that you know we don't blame the person and we don't, You know, use languages that they feel that we're judging them. I mean I think that's really important, um, and you know, many of us are very good at reading the person in front of us and if we've said something and they've, you know, sort of leaned back and say, oh, you know, we can always recover as long as we do it respectfully. And then of course, what you're actually trying to achieve, you know, um, often the goals of um the person in,